×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
戻る Agenda
Session 27: CMC Considerations in Pediatric Development
Session Chair(s)
Albert S. Yehaskel, MBA
President and CEO
Refuah Global Pharmaceutical Development, Inc., United States
- Pediatric Regulatory Considerations
- The Best Pharmaceuticals for Children’s Act (BPCA)
- Pediatric Research Equity Act (PREA)
- FDA – Pediatric Study Plans
- Introduction
- Contents of a PSP
- Pediatric Formulations Development